XML 40 R28.htm IDEA: XBRL DOCUMENT v3.24.3
Revenue from Contracts with Customers (Tables)
9 Months Ended
Sep. 30, 2024
Revenue from Contracts with Customers  
Summary of product revenue provision and allowance categories

The following tables summarize activity in each of the Company’s product revenue provision and allowance categories for the nine months ended September 30, 2024 and 2023:

    

Trade

Rebates and

Product

Allowances and

Incentives (1)

Returns (2)

Chargebacks (3)

Balance as of December 31, 2023

$

149,826

$

77,505

$

20,917

Provision related to current period sales

303,570

33,587

124,194

Acquired from Ironshore

42,515

36,588

5,011

Changes in estimate related to prior period sales

(1,634)

2,419

(85)

Credits/payments made

(296,433)

(34,069)

(120,611)

Balance as of September 30, 2024

$

197,844

$

116,030

$

29,426

    

    

Trade

Rebates and

Product

Allowances and

Incentives (1)

Returns (2)

Chargebacks (3)

Balance as of December 31, 2022

$

156,937

$

73,554

$

22,058

Provision related to current period sales

325,725

31,904

112,550

Changes in estimate related to prior period sales

2

3,722

589

Credits/payments made

(315,170)

(31,662)

(113,263)

Balance as of September 30, 2023

$

167,494

$

77,518

$

21,934

(1)Provisions for rebates and incentives include managed care rebates, government rebates and co-pay program incentives. Provisions for rebates and incentives are deducted from gross revenues at the time revenues are recognized and are included in accrued rebates, returns and discounts in the Company’s Condensed Consolidated Balance Sheets.
(2)Provisions for product returns are deducted from gross revenues at the time revenues are recognized and are included in accrued rebates, returns and discounts in the Company’s Condensed Consolidated Balance Sheets.
(3)Provisions for trade allowances and chargebacks include fees for distribution service fees, prompt pay discounts, and chargebacks. Trade allowances and chargebacks are deducted from gross revenue at the time revenues are recognized and are recorded as a reduction to accounts receivable in the Company’s Condensed Consolidated Balance Sheets.
Schedule of disaggregation of revenue

Three Months Ended September 30,

Nine Months Ended September 30,

2024

2023

2024

2023

Belbuca

$

53,197

$

45,447

$

156,058

$

132,795

Xtampza ER

49,492

    

39,800

139,876

128,914

Nucynta IR

25,361

24,906

76,524

80,963

Nucynta ER

19,773

22,634

58,231

62,941

Jornay PM

7,961

7,961

Symproic

3,517

3,922

10,850

11,409

Total product revenues, net

$

159,301

$

136,709

$

449,500

$

417,022